PRP Concentrate Arm 2

PreclinicalBiologic

HHealeon Medical Inc

PRP Concentrate Arm 2 is one of 26 biologic programs targeting Osteoarthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Platelet Rich Plasma

25 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Enbrel

IImmunex

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Paracetamol

GSK

Preclinical

4 10

Naproxen Sodium

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ARecruiting

Osteoarthritis

NCT04238143

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Recruiting·HHealeon Medical Inc·N/A·NCT04238143·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PRP Concentrate Arm 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRP Concentrate Arm 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRP Concentrate Arm 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healeon Medical Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHealeon Medical Inc

PRP Concentrate Arm 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News